← boardnext 2026-11
ZURA
Zura Bio Incdistress 3/10 · well-funded / low risk$5.37-1%today-24% from 52w high
Lead: hidradenitis suppurativa
Revenue
pre-revenue
Liquidity
$226M
Runway
3.1 yrs
Shares 1y
+46%
Price & events
-16.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
+2.3%
1W
+24.7%
1M
-2.7%
3M
-15.6%
6M
+217.8%
1Y
+39.8%
2Y
—
5Y
-25.8%
All
Overview
- Market Cap
- $510.14M
- Volume
- 26.23K
- 52 Week Range
- $1.29 – $7.04
- Total Shares
- 95.00M
- Float Shares
- 50.75M
- Short %
- 13.03%
- % Held by Insiders
- 21.51%
- % Held by Institutions
- 78.56%
- RVOL
- 0.02x
- Beta
- -0.04
Pipeline stages · 1 programs
Tibulizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 2 | Tibulizumab Dose A, Tibulizumab Dose B | Hidradenitis Suppurativa (HS) | — | active not recruiting |
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 2 | Tibulizumab | Systemic Sclerosis (SSc), Scleroderma | — | recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 7
- first half of 2027Guided 55%readoutPhase 2tibulizumab · Topline results from Phase 2 TibuSURE study.SEC 8-K
- Q4 2026Guided 70%readoutPhase 2tibulizumab · Topline data from Phase 2 studySEC 8-K
- by year end 2026Guided 40%trial initiationsecondaryPhase 2tibulizumab · Initiate Phase 2 study for tibulizumab in a third indicationSEC 8-K
- Q3 2026Guided 70%readoutPhase 2tibulizumab · Topline results from TibuSHIELD Phase 2 trial in hidradenitis suppurativaSEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
- March 5–7, 2026conferencedata presentationsecondaryPhase 2tibulizumab · Poster presentation of TibuSURE trial design at Systemic Sclerosis World Congress.SEC 8-K
- May 20, 2025trial initiationsecondaryPhase 2tibulizumab · Launched global Phase 2 TibuSHIELD study to evaluate tibulizumab in adults with moderate to severe HS.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $16 (+192% upside) · 6 analysts
- 2026-07-08William BlairOutperform
- 2026-07-01WedbushOutperform
- 2026-03-23Chardan CapitalBuy
- 2026-03-20OppenheimerOutperform
- 2026-02-09WedbushOutperform
- 2025-11-14Chardan CapitalBuy
Competitors — hidradenitis suppurativa
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- PFEPFIZER INC$142.2B · D3
- SNYSanofi$52.5B · D1
- INCYINCYTE CORP$23.1B · D0
- INSMINSMED Inc$22.9B · D2
- KYMRKymera Therapeutics, Inc.$9.1B · D5
- MLTXMoonLake Immunotherapeutics$1.4B · D4
- AVTXAvalo Therapeutics, Inc.$941M · D8
Recent news
- 2026-07-08What's Going on With Zura Bio Stock Wednesday? - Zura Bio (NASDAQ:ZURA) - Benzinga
- 2026-07-08Zura Bio navigates growth path amid biotech volatility - Ad-hoc-news.de
- 2026-07-08William Blair initiates Zura Bio stock with outperform rating - Investing.com
- 2026-06-22Zura Bio (ZURA) VP details share, RSU and option holdings - Stock Titan
- 2026-06-22Zura Bio (ZURA) director Amit Munshi granted 51,000 share options at $3.62 - Stock Titan
- 2026-05-06JPMorgan reports 4.47M Zura Bio holdings (NASDAQ: ZURA) — 4.7% stake - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.